|
Jul 24
|
Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance
|
|
Jun 18
|
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China
|
|
Jan 5
|
Brokers Are Upgrading Their Views On Cosmo Pharmaceuticals N.V. (VTX:COPN) With These New Forecasts
|
|
Dec 18
|
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues Pushing Shares 37% Higher
|